Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $48.6 million.

  • Spero Therapeutics' Cash & Current Investments fell 3627.47% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year decrease of 3627.47%. This contributed to the annual value of $52.9 million for FY2024, which is 3071.28% down from last year.
  • According to the latest figures from Q3 2025, Spero Therapeutics' Cash & Current Investments is $48.6 million, which was down 3627.47% from $31.2 million recorded in Q2 2025.
  • Over the past 5 years, Spero Therapeutics' Cash & Current Investments peaked at $146.4 million during Q4 2021, and registered a low of $31.2 million during Q2 2025.
  • For the 5-year period, Spero Therapeutics' Cash & Current Investments averaged around $82.1 million, with its median value being $77.7 million (2023).
  • Per our database at Business Quant, Spero Therapeutics' Cash & Current Investments tumbled by 5912.56% in 2022 and then skyrocketed by 8599.1% in 2023.
  • Spero Therapeutics' Cash & Current Investments (Quarter) stood at $146.4 million in 2021, then decreased by 25.47% to $109.1 million in 2022, then tumbled by 30.04% to $76.3 million in 2023, then plummeted by 30.71% to $52.9 million in 2024, then fell by 8.08% to $48.6 million in 2025.
  • Its last three reported values are $48.6 million in Q3 2025, $31.2 million for Q2 2025, and $48.9 million during Q1 2025.